Profusa, Inc. (PFSA): Entry into a Material Definitive Agreement

Profusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed, the Company is party to a Securities Purchase Agreement, dated as of February 11, 2025 (as amended, the “Purchase Agreement”), by and among the Company, Ascent Partners Fund LLC, a Delaware limited lia

Event · Offering
Instrument
Senior Secured Convertible Promissory Note
Gross proceeds
$700,000.00
Coupon
7% per annum
Maturity
October 15, 2027

Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.

Original reporting
Published Oct 15, 2026, 10:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 10:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$PFSA
Bearish
high confidence
Mentioned
$PFSA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PFSABearishMed
01

Why it matters

The note adds $769k of senior secured debt and convertible equity potential, which may dilute existing shareholders and increase leverage.

02

Market read

A primary disclosure of a financing instrument that could affect PFSA's share price through dilution and debt considerations.

03

What to watch

Potential for the note to be prepaid after a subsequent equity offering, reducing dilution risk.

Relevance 6/10Novelty 8/10Timing: effective immediately on filing date

Background

Profusa Inc. (NASDAQ: PFSA) is a micro‑cap biotech developing diagnostic technologies. The filing details a financing transaction with Ascent Partners Fund.

Company-level read

Ticker impact

$PFSABearishHigh confidence
Context

Profusa filed an 8‑K reporting issuance of a $769,230 senior secured convertible note with a $4.28 conversion price.

Expected impact

downward pressure as investors price in dilution risk and higher leverage

Evidence & confidence

New debt and conversion rights increase share supply; interest rate and default provisions add risk.

Market effects

Limited to biotech financing trends; may signal increased use of convertible notes for capital raises.

Primarily affects US micro‑cap biotech investors.

Low; no broader market impact.

Counterpoint

If the note converts at a floor price above current levels, it could provide upside for shareholders.

Key entities

  • Profusa, Inc.

    Issuer of the convertible note.

  • Ascent Partners Fund LLC

    Purchaser and collateral agent for the note.

Related articles

$PFSALow

Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company

Profusa, Inc. (PFSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of w

$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

$PFSAMedAI 8/10

PFSA Stock Falls 19% Amid Diagnostics Acquisition News

Profusa (PFSA) said it signed a non-binding term sheet to acquire a privately held commercial diagnostics and toxicology testing company. The target estimates 2025 net revenues of about $111 million. Profusa would issue shares equal to 19.99% plus non-voting convertible preferred stock, subject to approval, and expects about $7 million financing via convertible notes. PFSA shares fell sharply after the news.